Domenica Lorusso

Via Francesco Nava 31
Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 443 publications

Inavolisib for PIK3CA-mutated advanced endometrial cancer: a multicentric, phase II, MITO END-4 trial.

Inavolisib for PIK3CA-mutated advanced endometrial cancer: a multicentric, phase II, MITO END-4 trial.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: April 27, 2026

Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer.

Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer.

Journal: Gynecologic oncology

Published: April 12, 2026

The TRUST trial in ovarian cancer: a missed opportunity or a turning point? The position of the Italian MITO group.

The TRUST trial in ovarian cancer: a missed opportunity or a turning point? The position of the Italian MITO group.

Journal: Frontiers in oncology

Published: April 11, 2026

Sentinel lymph node mapping in gynecologic oncology: technical tips and common pitfalls.

Sentinel lymph node mapping in gynecologic oncology: technical tips and common pitfalls.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: April 04, 2026

Hitting the mark-or missing it? The promise and peril of biomarkers in endometrial cancer.

Hitting the mark-or missing it? The promise and peril of biomarkers in endometrial cancer.

Journal: Gynecologic oncology

Published: March 19, 2026

Somatic BRCA1 and BRCA2 detection in homologous recombination deficiency testing: concordance of four sequencing workflows with the Myriad myChoice companion diagnostic.

Somatic BRCA1 and BRCA2 detection in homologous recombination deficiency testing: concordance of four sequencing workflows with the Myriad myChoice companion diagnostic.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: March 17, 2026

Challenges in the use of the European Society for Radiotherapy and Oncology-European Organisation for Research and Treatment of Cancer oligometastatic disease classification system in ovarian cancer.

Challenges in the use of the European Society for Radiotherapy and Oncology-European Organisation for Research and Treatment of Cancer oligometastatic disease classification system in ovarian cancer.

Journal: The Lancet. Oncology

Published: March 04, 2026

Consensus statements from the first Gynecologic Cancer InterGroup Cervical Cancer Consensus Conference in Clinical Research.

Consensus statements from the first Gynecologic Cancer InterGroup Cervical Cancer Consensus Conference in Clinical Research.

Journal: The Lancet. Oncology

Published: February 24, 2026

Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial.

Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial.

Journal: Lancet (London, England)

Published: February 10, 2026

Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study.

Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study.

Journal: Gynecologic oncology

Published: February 02, 2026

Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775.

Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775.

Journal: Journal for immunotherapy of cancer

Published: January 20, 2026

Cost-effectiveness of pembrolizumab as a treatment for FIGO 2014 stage III-IVA cervical cancer in the United States.

Cost-effectiveness of pembrolizumab as a treatment for FIGO 2014 stage III-IVA cervical cancer in the United States.

Journal: Gynecologic oncology

Published: January 20, 2026

Showing 1-12 of 443

Last Updated: 09/26/2026